Morgan Stanley
PRLD icon

Morgan Stanley’s Prelude Therapeutics PRLD Stock Holding History

Morgan Stanley’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.69M Buy
503,860
+181,699
+56% +$791K ﹤0.01% 4669
2026
Q1 		$1.1M Sell
322,161
-12,755
-4% -$33.4K ﹤0.01% 5093
2025
Q4 		$971K Buy
334,916
+50,713
+18% +$85.6K ﹤0.01% 5199
2025
Q3 		$409K Sell
284,203
-179
-0.1% -$179 ﹤0.01% 5595
2025
Q2 		$230K Sell
284,382
-18,397
-6% -$15.9K ﹤0.01% 5797
2025
Q1 		$233K Sell
302,779
-62,380
-17% -$58.2K ﹤0.01% 5670
2024
Q4 		$466K Buy
365,159
+41,470
+13% +$55K ﹤0.01% 5443
2024
Q3 		$670K Buy
323,689
+36,335
+13% +$168K ﹤0.01% 5261
2024
Q2 		$1.09M Sell
287,354
-8,851
-3% -$36K ﹤0.01% 4902
2024
Q1 		$1.4M Sell
296,205
-2,591
-0.9% -$10.1K ﹤0.01% 4780
2023
Q4 		$1.28M Buy
298,796
+54,326
+22% +$165K ﹤0.01% 4785
2023
Q3 		$755K Buy
244,470
+49,144
+25% +$184K ﹤0.01% 4956
2023
Q2 		$879K Buy
195,326
+53,664
+38% +$321K ﹤0.01% 4909
2023
Q1 		$807K Buy
141,662
+51,713
+57% +$315K ﹤0.01% 4979
2022
Q4 		$543K Sell
89,949
-87,839
-49% -$563K ﹤0.01% 5200
2022
Q3 		$1.18M Sell
177,788
-303,000
-63% -$2.04M ﹤0.01% 4789
2022
Q2 		$2.51M Sell
480,788
-65,687
-12% -$334K ﹤0.01% 4357
2022
Q1 		$3.77M Sell
546,475
-299,239
-35% -$2.74M ﹤0.01% 3983
2021
Q4 		$10.5M Buy
845,714
+88,927
+12% +$1.45M ﹤0.01% 2899
2021
Q3 		$23.6M Buy
756,787
+624,622
+473% +$20.2M ﹤0.01% 1914
2021
Q2 		$3.78M Buy
132,165
+108,091
+449% +$3.85M ﹤0.01% 4074
2021
Q1 		$1.04M Sell
24,074
-3,054
-11% -$203K ﹤0.01% 4708
2020
Q4 		$1.94M Buy
27,128
+13,973
+106% +$695K ﹤0.01% 4183
2020
Q3 		$396K Buy
+13,155
New +$371K ﹤0.01% 4754

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Morgan Stanley's PRLD Position: Q2 2026 in Review

Morgan Stanley increased its Prelude Therapeutics (PRLD) stake by 56% in Q2 2026, buying an estimated $791K and bringing the position to 503,860 shares worth $2.69M. The position accounts for ﹤0.01% of the portfolio, ranked #4669.

Morgan Stanley first reported a position in PRLD in Q3 2020 and has held it in 24 quarters since. The position peaked at $23.6M in Q3 2021. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Morgan Stanley held 503,860 shares of Prelude Therapeutics worth $2.69M as of Q2 2026.
  • Morgan Stanley bought 181,699 Prelude Therapeutics shares in Q2 2026, an estimated $791K.
  • Prelude Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #4669 holding.
  • Morgan Stanley first reported a position in Prelude Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • Morgan Stanley's Prelude Therapeutics position peaked at $23.6M in Q3 2021.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.